Each vial contains a stable population of 2,000,000 Neuro-2a cells expressing the NucLight Red fluorescent protein, restricted to the nucleus. Parent Neuro-2a cells were purchased from ATCC (Cat# CCL-131). Neuro-2a cells were transduced with the Incucyte® NucLight Red Lentivirus (Cat# 4476; EF1α, puromycin). 48 hours post infection, the complete population of cells were grown for 3-5 days in complete growth media containing 2 µg/ml Puromycin to select for cells expressing NucLight Red. NucLight Red expressing cells are maintained in complete media containing 0.5 µg/ml Puromycin. Following selection, a panel of validation assays designed to evaluate the effects of nuclear label expression on functional cell biology was completed. These assays include comparisons of cell morphology, growth/proliferation, and neurite outgrowth between stable populations and the parent populations from which they were derived. In addition, our complete NucLight Red cell catalog has been certified mycoplasma free by ATCC and the stable populations of Neuro-2a have been authenticated using Idexx Radil’s CellCheck™ analysis.